{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T22:04:52Z","timestamp":1778796292697,"version":"3.51.4"},"reference-count":37,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T00:00:00Z","timestamp":1597017600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0237383","type":"journal-article","created":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T17:25:57Z","timestamp":1597080357000},"page":"e0237383","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":16,"title":["Benefit of serum drug monitoring complementing urine analysis to assess adherence to antihypertensive drugs in first-line therapy"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6718-2692","authenticated-orcid":true,"given":"Sabrina","family":"Ritscher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milena","family":"Hoyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Coralie","family":"Georges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cora","family":"Wunder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Wallemacq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"Persu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Oberm\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan W.","family":"Toennes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2020,8,10]]},"reference":[{"key":"pone.0237383.ref001","doi-asserted-by":"crossref","first-page":"A1819","DOI":"10.1016\/S0735-1097(18)32360-X","article-title":"Worldwide prevalence of hypertension: A pooled meta-analysis of 1670 studies in 71 countries with 29.5 million participants","volume":"71","author":"H Salem","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"pone.0237383.ref002","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1097\/00004872-199210000-00001","article-title":"A meta-analysis of outcome trials in elderly hypertensives","volume":"10","author":"L Thijs","year":"1992","journal-title":"J Hypertens"},{"key":"pone.0237383.ref003","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(97)05381-6","article-title":"Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension","volume":"350","author":"JA Staessen","year":"1997","journal-title":"Lancet"},{"key":"pone.0237383.ref004","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1161\/CIRCRESAHA.116.304723","article-title":"The epidemiology of blood pressure and its worldwide management","volume":"116","author":"K Rahimi","year":"2015","journal-title":"Circ Res"},{"key":"pone.0237383.ref005","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jchromb.2018.04.038","article-title":"Quantification of 21 antihypertensive drugs in serum using UHPLC-MS\/MS","volume":"1089","author":"POM Gundersen","year":"2018","journal-title":"Journal of Chromatography B"},{"key":"pone.0237383.ref006","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1474-5151(03)00091-4","article-title":"Adherence to long-term therapies: evidence for action","volume":"2","author":"S de Geest","year":"2003","journal-title":"Eur J Cardiovasc Nurs"},{"key":"pone.0237383.ref007","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3109\/08037051.2015.1121706","article-title":"Adherence to medication and drug monitoring in apparent treatment-resistant hypertension","volume":"25","author":"PA Esk\u00e5s","year":"2016","journal-title":"Blood Press"},{"key":"pone.0237383.ref008","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1161\/HYPERTENSIONAHA.116.07464","article-title":"Evaluation of Adherence Should Become an Integral Part of Assessment of Patients With Apparently Treatment-Resistant Hypertension","volume":"68","author":"E Berra","year":"2016","journal-title":"Hypertension"},{"key":"pone.0237383.ref009","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-662-57386-0","volume-title":"Arzneiverordnungs-Report 2018","author":"U Schwabe","year":"2018"},{"key":"pone.0237383.ref010","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-662-47186-9","volume-title":"Arzneiverordnungs-Report 2015. Aktuelle Daten, Kosten, Trends und Kommentare","author":"U Schwabe","year":"2015"},{"key":"pone.0237383.ref011","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11906-018-0812-z","article-title":"The Global Epidemic of the Metabolic Syndrome","volume":"20","author":"MG Saklayen","year":"2018","journal-title":"Curr Hypertens Rep"},{"key":"pone.0237383.ref012","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0140-6736(07)60108-1","article-title":"Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis","volume":"369","author":"WJ Elliott","year":"2007","journal-title":"Lancet"},{"key":"pone.0237383.ref013","doi-asserted-by":"crossref","first-page":"15652","DOI":"10.1038\/s41598-019-52164-y","article-title":"Evaluation of the dose-related concentration approach in therapeutic drug monitoring of diuretics and \u03b2-blockers\u2014drug classes with low adherence in antihypertensive therapy","volume":"9","author":"S Ritscher","year":"2019","journal-title":"Sci Rep"},{"key":"pone.0237383.ref014","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.forsciint.2004.11.014","article-title":"Instability of calcium channel antagonists during sample preparation for LC-MS-MS analysis of serum samples","volume":"156","author":"AB Baranda","year":"2006","journal-title":"Forensic Sci Int"},{"key":"pone.0237383.ref015","unstructured":"Peters F T, Hartung M, Herbold M, Schmitt G, Daldrup T, Mu\u00dfhoff F. Requirements for the validation of analytical methods. Appendix B: To the GTFCh Guidelines for quality assurance in forensic-toxicological analyses; 2009. Available: https:\/\/www.gtfch.org\/cms\/images\/stories\/files\/Appendix%20B%20GTFCh%2020090601.pdf. Accessed 28 October 2018."},{"key":"pone.0237383.ref016","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/aheh.19930210603","article-title":"Calculation of Detection Limit, Identification Limit and Determination Limit according to DIN 32645 with the","volume":"21","author":"M Kolb","year":"1993","journal-title":"Aid of a Computer Programs. Acta hydrochim hydrobiol"},{"key":"pone.0237383.ref017","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/00007691-200502000-00010","article-title":"Quantitative determination of the calcium channel antagonists amlodipine, lercanidipine, nitrendipine, felodipine, and lacidipine in human plasma using liquid chromatography-tandem mass spectrometry","volume":"27","author":"AB Baranda","year":"2005","journal-title":"Ther Drug Monit"},{"key":"pone.0237383.ref018","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jpha.2012.03.008","article-title":"Simultaneous determination of telmisartan and amlodipine in human plasma by LC-MS\/MS and its application in a human pharmacokinetic study","volume":"2","author":"VB Ravi","year":"2012","journal-title":"J Pharm Anal"},{"key":"pone.0237383.ref019","first-page":"1","volume":"16","author":"M Schulz","year":"2012","journal-title":"Therapeutic and toxic blood concentrations of nearly"},{"key":"pone.0237383.ref020","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/jms.630","article-title":"Screening for dihydropyridine calcium channel blockers in plasma by automated solid-phase extraction and liquid chromatography\/tandem mass spectrometry","volume":"39","author":"CA Mueller","year":"2004","journal-title":"J Mass Spectrom"},{"key":"pone.0237383.ref021","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1177\/009127000004001210","article-title":"Dose response and safety of telmisartan in patients with mild to moderate hypertension","volume":"40","author":"DH Smith","year":"2000","journal-title":"J Clin Pharmacol"},{"key":"pone.0237383.ref022","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002343","article-title":"Adherence to Antihypertensive Medication in Treatment-Resistant Hypertension Undergoing Renal Denervation","volume":"5","author":"RE Schmieder","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"pone.0237383.ref023","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-0043-116492","article-title":"Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017","volume":"51","author":"C Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"pone.0237383.ref024","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1097\/HJH.0000000000001940","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension","volume":"36","author":"B Williams","year":"2018","journal-title":"J Hypertens"},{"key":"pone.0237383.ref025","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1365-2125.1986.tb02874.x","article-title":"The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily","volume":"22","author":"JK Faulkner","year":"1986","journal-title":"Br J Clin Pharmacol"},{"key":"pone.0237383.ref026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00005344-199729002-00002","article-title":"Clinical Pharmacokinetics of Lercanidipine","author":"M Barchielli","year":"1997","journal-title":"J Cardiovasc Pharmacol"},{"issue":"Suppl 1","key":"pone.0237383.ref027","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1038\/sj.jhh.1000991","article-title":"Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension","volume":"14","author":"ZH Israili","year":"2000","journal-title":"J Hum Hypertens"},{"key":"pone.0237383.ref028","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1136\/heartjnl-2013-305063","article-title":"High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS\/MS) urine analysis","volume":"100","author":"M Tomaszewski","year":"2014","journal-title":"Heart"},{"key":"pone.0237383.ref029","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1080\/08037051.2019.1599814","article-title":"Adherence to antihypertensive drug treatment in patients with apparently treatment-resistant hypertension in the INSPiRED pilot study","volume":"28","author":"C Wunder","year":"2019","journal-title":"Blood Press"},{"key":"pone.0237383.ref030","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/bdd.282","article-title":"Amlodipine bioequivalence study: quantification by liquid chromatography coupled to tandem mass spectrometry","volume":"22","author":"M Carvalho","year":"2001","journal-title":"Biopharm Drug Dispos"},{"key":"pone.0237383.ref031","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jpha.2015.09.001","article-title":"Determination of lercanidipine in human plasma by an improved UPLC-MS\/MS method for a bioequivalence study","volume":"6","author":"DV Chaudhary","year":"2016","journal-title":"J Pharm Anal"},{"key":"pone.0237383.ref032","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s002280050471","article-title":"Pharmacokinetics and safety of candesartan cilexetil in subjects with normal and impaired liver function","volume":"54","author":"JF Hoogkamer","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"issue":"Suppl 2","key":"pone.0237383.ref033","first-page":"S29","article-title":"Bioavailability of candesartan is unaffected by food in healthy volunteers administered candesartan cilexetil","volume":"11","author":"JG Riddell","year":"1997","journal-title":"J Hum Hypertens"},{"key":"pone.0237383.ref034","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1177\/009127000004001207","article-title":"Pharmacokinetics and safety of intravenous and oral telmisartan 20 mg and 120 mg in subjects with hepatic impairment compared with healthy volunteers","volume":"40","author":"J Stangier","year":"2000","journal-title":"J Clin Pharmacol"},{"key":"pone.0237383.ref035","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1177\/147323000002800401","article-title":"Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients","volume":"28","author":"J Stangier","year":"2000","journal-title":"J Int Med Res"},{"key":"pone.0237383.ref036","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3797\/scipharm.1009-01","article-title":"Formulation and bioequivalence of two valsartan tablets after a single oral administration","volume":"79","author":"AN Zaid","year":"2011","journal-title":"Sci Pharm"},{"key":"pone.0237383.ref037","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s002280050259","article-title":"Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man","volume":"52","author":"G Flesch","year":"1997","journal-title":"Eur J Clin Pharmacol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0237383","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,6]],"date-time":"2022-11-06T11:41:08Z","timestamp":1667734868000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0237383"}},"subtitle":[],"editor":[{"given":"Tatsuo","family":"Shimosawa","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2020,8,10]]},"references-count":37,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,8,10]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0237383","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,10]]}}}